Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody. - Wikidata - awgldk - TriplyDB

Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody.

Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody.

http://www.wikidata.org/entity/Q34455259

about

Oncolytic virotherapy of canine and feline cancer Trial Watch:: Oncolytic viruses for cancer therapy Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF.Evaluation of a new recombinant oncolytic vaccinia virus strain GLV-5b451 for feline mammary carcinoma therapy Antigen profiling analysis of vaccinia virus injected canine tumors: oncolytic virus efficiency predicted by boolean models.Characterization and evaluation of a new oncolytic vaccinia virus strain LIVP6.1.1 for canine cancer therapy Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy.Newcastle Disease Virus: Potential Therapeutic Application for Human and Canine Lymphoma.On the potential of oncolytic virotherapy for the treatment of canine cancers.Vitamin k2, a naturally occurring menaquinone, exerts therapeutic effects on both hormone-dependent and hormone-independent prostate cancer cells Update on oncolytic viral therapy - targeting angiogenesis Canine brain tumours: a model for the human disease?State of play and clinical prospects of antibody gene transfer.Anti-tumour activity of oncolytic Western Reserve vaccinia viruses in canine tumour cell lines, xenografts, and fresh tumour biopsies.Establishment and characterization of a canine soft tissue sarcoma patient-derived xenograft model.Growth Factors and COX2 Expression in Canine Perivascular Wall Tumors.Safety of an Oncolytic Myxoma Virus in Dogs with Soft Tissue Sarcoma

P2860

Q27008306-3CBF65EE-E8E1-40CD-B025-8B5C085B7DE8 Q27021951-7CE0BDC5-CC52-458F-897D-CC60019AAA40 Q33769835-EDE669CE-A5BF-45EB-A51E-FC35AAE20B96 Q34005213-98603CEB-6219-41C4-96A6-B49D97D89517 Q34142957-F088FFBC-3FDF-4BB9-A855-4EB8FAA07B2B Q34307934-18204C9B-2070-4F4B-ABA1-7C4258B43327 Q35895339-4D318A96-8A95-47E0-AB25-E2848D3CD012 Q36507259-CD3B26E2-071B-4071-9530-E2290769004F Q37031925-A11AB2D8-C531-47D3-8C20-39CB086F9E9D Q37156128-0EB15174-600E-4144-9C5C-A58FE7B0DDBB Q38128561-CB5DBE37-0074-4651-B39E-F2698643BF4F Q38491009-C5611A7A-9BB3-4501-97C5-AEC4FABEEC25 Q38737706-4336558A-E77E-471B-BF9F-B6231B12880E Q41706553-AD88D478-EEFD-4E49-9D3B-9D5F94F00DFE Q53143903-64DFE8D2-64BA-4494-A55C-F1352D68E24C Q54283149-B7D78523-6073-4C37-BFCE-AD1621A24166 Q59117175-C07BB680-764C-4ED6-9DE2-5A9A0DE541B7

P2860

Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody.

http://www.wikidata.org/entity/Q34455259

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Virotherapy of canine tumors w ...... ti-VEGF single-chain antibody.

@ast

Virotherapy of canine tumors w ...... ti-VEGF single-chain antibody.

@en

Virotherapy of canine tumors w ...... ti-VEGF single-chain antibody.

@nl

type

label

Virotherapy of canine tumors w ...... ti-VEGF single-chain antibody.

@ast

Virotherapy of canine tumors w ...... ti-VEGF single-chain antibody.

@en

Virotherapy of canine tumors w ...... ti-VEGF single-chain antibody.

@nl

prefLabel

Virotherapy of canine tumors w ...... ti-VEGF single-chain antibody.

@ast

Virotherapy of canine tumors w ...... ti-VEGF single-chain antibody.

@en

Virotherapy of canine tumors w ...... ti-VEGF single-chain antibody.

@nl

P1433

Q34455259-1C2CBA0D-8B32-4009-9E96-490103B257F4

P1476

Q34455259-7B8607E0-07F1-4245-9FB5-AD97A30F1167

P2093

Q34455259-1196F213-187E-4E24-AD79-2848D7F3CE21

Q34455259-42E02248-0848-4240-8D34-981530B4B9B8

Q34455259-85D81637-582F-41D2-B5FC-8AA8A1D250F3

Q34455259-8B3D606A-E670-421A-A216-9ABC7EDEE585

Q34455259-A9ACCFC9-B312-4579-B626-ABBC8B9A5E87

Q34455259-B42B371A-0971-43FA-8F17-FD3221E8BDEC

Q34455259-BF23C7D0-864D-46E3-AF7C-C60AB5BA1336

Q34455259-C56600F4-214F-42A0-8995-584887344DE7

P2860

Q34455259-09CFCD46-C422-40EB-91C5-61A10EDE6DE7

Q34455259-0CC95586-AFE6-4C1D-97F2-8D7F99F29711

Q34455259-11EFD7A3-D035-413F-990F-6D357468B14A

Q34455259-1F61CABA-05DA-43F2-88EF-46F01FF5A575

Q34455259-206A848D-B011-450B-88F3-7BA6E37AF1A0

Q34455259-26F1434C-9E82-4264-BEFC-3A3AAFE0B114

Q34455259-2712D546-8A14-4647-9B1F-31D2F67B010B

Q34455259-369D4636-EDF5-4591-8DCB-73251BEB5A93

Q34455259-3A7CCF82-D421-4207-97FA-21910BBA8442

Q34455259-3D62A683-D69C-427C-9EAF-A1A3DE5483C5

P304

Q34455259-2FA9FE8D-4020-4D35-A7AF-C7FF199C5152

P31

Q34455259-CDC282C9-A901-4CEF-BA99-2E618C9C2869

P356

Q34455259-B41AD0EC-7D65-4731-834B-4F938FAEC12C

P407

Q34455259-5E21C0F8-56C4-42C3-AB56-12C4BDC71D7C

P433

Q34455259-791B4298-96D8-4570-AC4D-68D72AA497C7

P478

Q34455259-6021DADC-478A-48E6-AD1E-0793690B41D3

P50

Q34455259-0E522B89-D641-423B-8016-9BE2903833F6

P577

Q34455259-69FF84D4-3C6E-4207-B794-B6EE8FF5E859

P5875

Q34455259-340463F5-2FF2-4986-93F0-F818A781982B

P698

Q34455259-6E657438-05DB-428B-A2E9-7D47FCD8467E

P921

Q34455259-4EC02B66-FB9D-4AB6-9CB9-A87019FB87FC

Q34455259-C7243EE3-5E8F-4EED-A717-68052830BE66

P932

Q34455259-3FEB4625-79ED-418E-BC83-1202A827ACB5

P356

JOURNAL.PONE.0047472

P1433

P1476

Virotherapy of canine tumors w ...... ti-VEGF single-chain antibody.

@en

P2093

Alexa Frentzen

http://www.w3.org/2001/XMLSchema#string

Ingo Nolte

http://www.w3.org/2001/XMLSchema#string

Ivaylo Gentschev

http://www.w3.org/2001/XMLSchema#string

Marion Adelfinger

http://www.w3.org/2001/XMLSchema#string

Michael Hess

http://www.w3.org/2001/XMLSchema#string

Sandeep S Patil

http://www.w3.org/2001/XMLSchema#string

Stephanie Weibel

http://www.w3.org/2001/XMLSchema#string

Ulrike Donat

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy

The biology of VEGF and its receptors

Two new cases of polysomy 13 in canine prostate cancer

Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma

Efficient colonization and therapy of human hepatocellular carcinoma (HCC) using the oncolytic vaccinia virus strain GLV-1h68

Angiogenesis: an organizing principle for drug discovery?

Neutrophils and immunity: challenges and opportunities

Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN

Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.

Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68.

P304

e47472

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0047472

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Aladar A Szalay

P577

2012-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232612071

http://www.w3.org/2001/XMLSchema#string

P698

23091626

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

3473019

http://www.w3.org/2001/XMLSchema#string